Scientific Presentations
ForeseeHome
ARVO 2023
| April 2023
Predictive Value of Preferential Hyperacuity Perimetry in Identifying Patients at High Risk of Conversion to Neovascular AMD
Emily Chew, MDARVO 2023
| April 2023
A Tele-Ophthalmology Model for Remote Monitoring of Patients with Age-Related Macular Degeneration
Jennifer Jacobs, MDHawaiian Eye and Retina Meeting 2023
| January 2023
Update on Home Monitoring of AMD
Judy E. Kim, MDFDA Intended Use
ForeseeHome has not been approved by FDA for use other than described in the following Indication for Use: The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration as an aid in monitoring progression of disease factors causing metamorphopsia including, but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.
Media enquiries? Reach out to our Media Contact